Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities.
Together, the companies aim to bring new bioprocess solutions to customers that use digitaliation, in-silico approaches, and virtual monitoring and control of experiments.
As the first step in this new collaboration, Cytiva’s Bioreactor Scaler tool now includes Culture’s 250 mL bioreactor. The Bioreactor Scaler tool enables scaling between development and manufacturing. Scientists can identify scale-up or scale-down process control parameters by entering in their existing process details and cell line characteristics. The tool helps to de-risk scaling activities and ensure product quality. Teams can collaborate virtually from anywhere.
“Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and data produced from our collaborative platform will help them predict performance at the next level, whether it be clinical or commercial scale,” said Nicolas Pivet, Head of Automation, Controls, Digital and Learning, Cytiva. “You can accelerate the therapeutic process development.”
“We are thrilled by the prospect to advance upstream bioprocess development with a global leader in the development, manufacturing and delivery of therapeutics,” said Will Patrick, Chief Executive Officer of Culture Biosciences. “Digital technologies have greatly advanced other manufacturing sectors in recent years. We look forward to our work with Cytiva to bring similar innovation to upstream bioprocess development, for the benefit of both our customers and their patients.”
